Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel Free DMAA Stock Alerts

Drugs Made In America Acquisition (DMAA) Competitors

Drugs Made In America Acquisition logo
$10.75 -0.01 (-0.09%)
As of 09/3/2026 04:00 PM Eastern
Compare

DMAA vs. TUYA, PD, RSKD, MGIC, and MITK

Should you buy Drugs Made In America Acquisition stock or one of its competitors? Drugs Made In America Acquisition's main competitors and comparable companies include Tuya (TUYA), PagerDuty (PD), Riskified (RSKD), Magic Software Enterprises (MGIC), and Mitek Systems (MITK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Drugs Made In America Acquisition compare to Tuya?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Tuya (NYSE:TUYA) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Tuya has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
Tuya$321.79M3.21$57.89M$0.1117.27

11.5% of Tuya shares are owned by institutional investors. 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Comparatively, 2.1% of Tuya shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tuya had 3 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 3 mentions for Tuya and 0 mentions for Drugs Made In America Acquisition. Tuya's average media sentiment score of 0.29 beat Drugs Made In America Acquisition's score of 0.00 indicating that Tuya is being referred to more favorably in the news media.

Company Overall Sentiment
Drugs Made In America Acquisition Neutral
Tuya Neutral

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Tuya has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Tuya has a net margin of 20.16% compared to Drugs Made In America Acquisition's net margin of 0.00%. Tuya's return on equity of 6.74% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
Tuya 20.16%6.74%5.96%

Tuya has a consensus target price of $3.69, suggesting a potential upside of 94.21%. Given Tuya's stronger consensus rating and higher probable upside, analysts plainly believe Tuya is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tuya
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Tuya beats Drugs Made In America Acquisition on 12 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to PagerDuty?

Drugs Made In America Acquisition (NASDAQ:DMAA) and PagerDuty (NYSE:PD) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

PagerDuty has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
PagerDuty$492.55M2.25$173.85M$2.007.04

PagerDuty has a consensus price target of $12.56, indicating a potential downside of 10.78%. Given PagerDuty's stronger consensus rating and higher probable upside, analysts plainly believe PagerDuty is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PagerDuty
2 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.10

PagerDuty has a net margin of 37.50% compared to Drugs Made In America Acquisition's net margin of 0.00%. PagerDuty's return on equity of 18.52% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
PagerDuty 37.50%18.52%4.84%

Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, PagerDuty has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

97.3% of PagerDuty shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 6.0% of PagerDuty shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, PagerDuty had 21 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 21 mentions for PagerDuty and 0 mentions for Drugs Made In America Acquisition. PagerDuty's average media sentiment score of 0.68 beat Drugs Made In America Acquisition's score of 0.00 indicating that PagerDuty is being referred to more favorably in the news media.

Company Overall Sentiment
Drugs Made In America Acquisition Neutral
PagerDuty Positive

Summary

PagerDuty beats Drugs Made In America Acquisition on 12 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Riskified?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Riskified (NYSE:RSKD) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Riskified had 16 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 16 mentions for Riskified and 0 mentions for Drugs Made In America Acquisition. Riskified's average media sentiment score of 0.39 beat Drugs Made In America Acquisition's score of 0.00 indicating that Riskified is being referred to more favorably in the news media.

Company Overall Sentiment
Drugs Made In America Acquisition Neutral
Riskified Neutral

Drugs Made In America Acquisition has a net margin of 0.00% compared to Riskified's net margin of -4.23%. Drugs Made In America Acquisition's return on equity of 0.00% beat Riskified's return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
Riskified -4.23%-3.93%-2.79%

Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Riskified has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Riskified has a consensus target price of $6.50, indicating a potential downside of 6.47%. Given Riskified's stronger consensus rating and higher probable upside, analysts plainly believe Riskified is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Riskified
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

59.0% of Riskified shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Comparatively, 17.4% of Riskified shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Drugs Made In America Acquisition has higher earnings, but lower revenue than Riskified.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
Riskified$344.64M2.99-$27.57M-$0.11N/A

Summary

Riskified beats Drugs Made In America Acquisition on 9 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Magic Software Enterprises (NASDAQ:MGIC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Magic Software Enterprises has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Magic Software Enterprises has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magic Software Enterprises$603.22M1.41$36.88M$0.8121.46
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

24.7% of Magic Software Enterprises shares are owned by institutional investors. 4.5% of Magic Software Enterprises shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Magic Software Enterprises' average media sentiment score of 0.00 equaled Drugs Made In America Acquisition'saverage media sentiment score.

Company Overall Sentiment
Magic Software Enterprises Neutral
Drugs Made In America Acquisition Neutral

Magic Software Enterprises has a net margin of 6.61% compared to Drugs Made In America Acquisition's net margin of 0.00%. Magic Software Enterprises' return on equity of 16.28% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Magic Software Enterprises6.61% 16.28% 8.96%
Drugs Made In America Acquisition N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Magic Software Enterprises
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Magic Software Enterprises beats Drugs Made In America Acquisition on 8 of the 8 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Mitek Systems?

Mitek Systems (NASDAQ:MITK) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Mitek Systems currently has a consensus target price of $19.33, suggesting a potential upside of 2.56%. Given Mitek Systems' stronger consensus rating and higher probable upside, research analysts clearly believe Mitek Systems is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mitek Systems
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Mitek Systems has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

In the previous week, Mitek Systems had 1 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 1 mentions for Mitek Systems and 0 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.00 beat Mitek Systems' score of -0.27 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Mitek Systems Neutral
Drugs Made In America Acquisition Neutral

Mitek Systems has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mitek Systems$179.69M4.73$8.80M$0.4740.11
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

83.6% of Mitek Systems shares are owned by institutional investors. 2.2% of Mitek Systems shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Mitek Systems has a net margin of 11.39% compared to Drugs Made In America Acquisition's net margin of 0.00%. Mitek Systems' return on equity of 19.16% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Mitek Systems11.39% 19.16% 11.32%
Drugs Made In America Acquisition N/A N/A N/A

Summary

Mitek Systems beats Drugs Made In America Acquisition on 12 of the 13 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAA vs. The Competition

Export
MetricDrugs Made In America AcquisitionSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$261.22M$15.72B$29.51B$12.73B
Dividend YieldN/A3.40%2.73%8.86%
P/E RatioN/A139.9475.7825.25
Price / SalesN/A1,296.40591.9397.64
Price / CashN/A45.8947.3252.26
Price / BookN/A7.469.306.14
Net IncomeN/A$437.25M$678.51M$349.01M
7 Day PerformanceN/A-0.60%-0.81%-0.27%
1 Month Performance0.51%1.96%-0.99%0.68%
1 Year Performance4.78%5.39%185.90%14.84%

Drugs Made In America Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAA
Drugs Made In America Acquisition
0.3076 of 5 stars		$10.75
-0.1%		N/A+4.5%$261.22MN/AN/A2
TUYA
Tuya
4.1768 of 5 stars		$1.80
+2.6%		$3.69
+105.6%		-24.8%$977.77M$321.79M17.951,441
PD
PagerDuty
1.9185 of 5 stars		$12.30
+1.5%		$12.13
-1.4%		-9.7%$950.16M$492.55M6.031,155
RSKD
Riskified
2.4086 of 5 stars		$5.90
-0.8%		$6.50
+10.2%		+53.3%$874.10M$344.64MN/A780
MGIC
Magic Software Enterprises
N/A$17.38
flat		N/AN/A$853.36M$603.22M21.463,787

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Pass by August 7… or wait until 2027?
Right now, your phone is recording exactly where you are. It does this roughly every two minutes. Precise coor...
Crypto 101 Media | Sponsoredtc pixel